Retatrutide: The Triple Agonist Posting the Biggest Numbers Yet

Retatrutide is an investigational peptide that has drawn significant attention for obesity and metabolic trial results. Unlike single-target GLP-1 drugs, it acts on three receptors at once: which is why it is described as a triple agonist. This guide is the cluster hub: what it is, what trials show, what remains unknown, and where to go next for dosage, results and safety detail.

Short answer: Retatrutide (LY3437943) is a Lilly pipeline drug with some of the largest average weight-loss signals reported in obesity research. It is not approved. Trial GI side effects look familiar for the incretin class, with additional signals (such as dysesthesia) appearing as studies got larger.

Cluster map

Broader context: peptides for weight loss · what is GLP-1 · GLP-1 side effects.

Retatrutide is not an approved medication. It remains investigational. Nothing here is medical advice. Do not treat unregulated "research" vials as clinical retatrutide.

What is retatrutide?

Retatrutide (development code LY3437943) is a peptide developed for obesity and type 2 diabetes research. It belongs to the same broad incretin family as semaglutide and tirzepatide, but it engages an additional receptor.

It activates:

• GLP-1 receptors: appetite, satiety, glucose-dependent insulin response, slowed gastric emptying
• GIP receptors: incretin signaling linked to insulin secretion and metabolic effects (also targeted by tirzepatide)
• Glucagon receptors: the differentiator; intended to influence energy expenditure and liver fat metabolism in multi-agonist designs

That third arm is why people call it a triple agonist. For a deeper receptor walkthrough, see how retatrutide works.

Attribute	Retatrutide snapshot
Developer	Eli Lilly
Code name	LY3437943
Class	GIP / GLP-1 / glucagon receptor triple agonist
Typical trial route	Once-weekly subcutaneous injection
Regulatory status	Investigational (not FDA-approved as of this review)
Dosing interval in trials	Once weekly subcutaneous (half-life long enough to support weekly regimens in development summaries)

What the trials report

Phase 2 obesity (peer-reviewed)

In a Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al.), adults with obesity received weekly retatrutide or placebo for 48 weeks. Average body-weight change at the highest 12 mg dose was about −24%, versus about −2% on placebo. Mid doses (4–8 mg) also showed large average reductions.

Weight loss was already substantial by 24 weeks at higher doses and had not clearly plateaued by week 48, one reason the field paid attention.

Responder rates at higher doses were also high for standard milestones (5%, 10%, 15% body-weight loss). Full tables live on retatrutide results.

Type 2 diabetes Phase 2

A Lancet Phase 2 diabetes trial reported large HbA1c reductions at higher doses, about −2.0 percentage points at 24 weeks on the 12 mg arm (published −2.02%) versus roughly −1.4% on dulaglutide 1.5 mg, with concurrent weight loss. That matters because obesity drugs increasingly need a metabolic safety and efficacy story beyond scale weight alone.

Liver fat (MASLD) Phase 2a

A Nature Medicine Phase 2a study in metabolic dysfunction-associated steatotic liver disease reported large relative reductions in liver fat at higher doses, including a high fraction of participants reaching normal liver-fat thresholds at 12 mg in that small study. Striking, still early, and not a substitute for outcomes trials.

Phase 3 topline (not fully peer-reviewed)

Lilly’s TRIUMPH Phase 3 program has released topline figures describing average weight loss in the high 20% range over longer follow-up (for example, communications around TRIUMPH-4 in people with obesity and knee osteoarthritis, and later obesity readouts). Treat topline numbers as company announcements: directionally important, not yet the same as a complete peer-reviewed package for every endpoint.

Side effects reported in studies

The side-effect profile is broadly familiar for incretin drugs and is mostly gastrointestinal and dose-related:

Serious adverse events in Phase 2 were uncommon and broadly in a similar range to placebo, with dose-related discontinuations for tolerability. Full detail: retatrutide side effects.

Class-level GLP-1 thyroid C-cell warnings from rodent data apply as a class consideration for GLP-1-containing agents; no retatrutide-specific MTC signal is established in published trial summaries to date.

How dosing works in trials (summary)

There is no approved dose. Trials used once-weekly subcutaneous injections with stepwise escalation toward targets commonly discussed as 1, 4, 8 and 12 mg. Higher targets meant more average weight loss and more GI burden.

Do not copy forum "protocols." Read the dedicated retatrutide dosage page for the trial map and myth-busting.

How it compares

	Semaglutide	Tirzepatide	Retatrutide
Receptors	GLP-1	GIP + GLP-1	GIP + GLP-1 + glucagon
Obesity brand (US)	Wegovy	Zepbound	None yet
Evidence maturity	Large Phase 3 + outcomes	Large Phase 3 + labels	Strong Phase 2; Phase 3 ongoing/reading out
Practical today	Prescribable when appropriate	Prescribable when appropriate	Pipeline / trial access only

Cross-trial percent weight loss comparisons are imperfect (different populations, durations, lifestyle co-interventions). Still, retatrutide’s Phase 2 averages sit at the top of the published range. That does not make research-chemical retatrutide a substitute for Zepbound or Wegovy.

Deep dives:

• Tirzepatide vs retatrutide
• Semaglutide vs tirzepatide
• Retatrutide vs GLP-1

Approval status and access reality

Retatrutide is investigational. Until approval:

• There is no consumer prescribing information
• Quality, identity and sterility of gray-market products are uncontrolled
• Legitimate exposure is clinical trials (and later, if approved, pharmacies)

For status tracking language, see retatrutide FDA approval. FDA has also warned broadly about unapproved GLP-1-family products used for weight loss the same caution mindset applies here.

Who should care about this page

Useful if you are:

• Comparing pipeline obesity drugs to approved options
• Reading Phase 2/3 press and need a plain-language map
• Trying to separate trial drug from research-chemical marketing

Not a green light to:

• Self-source vials and invent a titration
• Delay indicated, approved care while waiting for a pipeline drug
• Assume before/after social posts equal trial results

Related tools and adjacent guides

• Category map: peptides for weight loss
• Safety class: GLP-1 side effects
• Handling literacy (general peptides): reconstitution guide, calculators

Unregulated product risk (read this before any "buy" search)

Search results for retatrutide are flooded with research-chemical vendors. A vial labeled retatrutide is not automatically:

• The same sequence and salt form as the clinical investigational product
• Sterile and endotoxin-controlled to pharmaceutical standards
• Accurately dosed after amateur reconstitution
• Legal for human use in your jurisdiction

FDA has warned about unapproved GLP-1-family products for weight loss. Multi-agonist gray-market products inherit that risk class. Legitimate research reading uses trial publications and company trial disclosures, not Instagram vendors.

If your goal is medical weight management today, the evidence-based path is an approved medicine under a clinician — see peptides for weight loss and semaglutide vs tirzepatide.

Timeline of public evidence (high level)

Stage	What became public	Why it matters
Early development	Triple-agonist design papers and early clinical work	Established mechanism rationale
Phase 2 obesity (NEJM)	~24% average loss at 12 mg / 48 weeks	Put retatrutide on the obesity map
Phase 2 diabetes / liver	HbA1c and liver-fat signals	Broadened metabolic story
Phase 3 TRIUMPH toplines	High-20% averages in announced trials	Registration-relevant, still awaiting full packages for some endpoints

Treat every new press release as provisional until methods and adverse-event tables are fully published.

Open questions the field still has to answer

1. Final labeled dose(s) and titration scheme (if approved)
2. Long-term maintenance and regain after dose reduction or stop
3. Comparative effectiveness vs tirzepatide in head-to-head designs
4. Full characterization of dysesthesia and other non-GI signals
5. Outcomes beyond weight (CV, hard liver endpoints, etc.) as programs mature
6. Real-world tolerability outside highly selected trial populations

The bottom line

Retatrutide is one of the most closely watched metabolic peptides of the decade: triple-receptor design, very large average weight-loss signals, and an incretin-like safety story with dose-limiting GI effects plus emerging Phase 3 signals to watch.

But "investigational" is the operative word. It is not approved, trial doses are not consumer protocols, and products sold online under the same name are not automatically the clinical molecule.

If you are researching retatrutide, treat current information as provisional, prefer primary trial sources, and talk to a qualified clinician about approved options if you need care today.

References

1. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. NEJM.

2. Rosenstock J, et al. Retatrutide for type 2 diabetes: phase 2 trial. The Lancet.

3. Sanyal AJ, et al. Retatrutide for MASLD: phase 2a trial. Nature Medicine.

4. Eli Lilly. TRIUMPH-4 Phase 3 topline announcement.

5. Coskun T, et al. LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist (mechanism / early development context).